We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.07B
AUM Growth
-$1.75B
Cap. Flow
-$771M
Cap. Flow %
-72.36%
Top 10 Hldgs %
79.25%
Holding
36
New
4
Increased
1
Reduced
17
Closed
11

Top Buys

Rank Stock Value
1
ICLR icon
Icon
ICLR
+$42.6M
2
MRK icon
Merck
MRK
+$39.7M
3
UNH icon
UnitedHealth
UNH
+$38.2M
4
APLS
Apellis Pharmaceuticals
APLS
+$15.7M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.89M

Top Sells

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$121M
2
HUM icon
Humana
HUM
+$106M
3
BAX icon
Baxter International
BAX
+$87.9M
4
CVS icon
CVS Health
CVS
+$78.7M
5
PTCT icon
PTC Therapeutics
PTCT
+$76.4M

Sector Composition

Rank Sector Weight
1 Healthcare 67.39%
2 Miscellaneous 32.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$309M 29%
500,000
-1,000,000
-67% -$572M
ZBH icon
2
Zimmer Biomet
ZBH
$19.2B
$91.2M 8.56%
1,000,000
-1,250,000
-56% -$121M
BAX icon
3
Baxter International
BAX
$13.5B
$86.3M 8.1%
2,850,000
-2,900,000
-50% -$87.9M
HUM icon
4
Humana
HUM
$46.3B
$73.3M 6.89%
300,000
-425,000
-59% -$106M
CVS icon
5
CVS Health
CVS
$119B
$72.4M 6.8%
1,050,000
-1,200,000
-53% -$78.7M
GMED icon
6
Globus Medical
GMED
$11.1B
$47.2M 4.43%
800,000
-450,000
-36% -$29.1M
ICLR icon
7
Icon
ICLR
$13.1B
$43.6M 4.1%
+300,000
New +$42.6M
ASND icon
8
Ascendis Pharma A/S
ASND
$16.3B
$43.1M 4.05%
250,000
-100,000
-29% -$16.3M
MRK icon
9
Merck
MRK
$366B
$39.6M 3.72%
+500,000
New +$39.7M
GSK icon
10
CALL
GSK
GSK
$102B
$38.4M 3.6%
1,000,000
– –
PFE icon
11
Pfizer
PFE
$159B
$36.4M 3.41%
1,500,000
-1,000,000
-40% -$23.3M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$12.5B
$33M 3.1%
600,000
+100,000
+20% +$5.89M
UNH icon
13
UnitedHealth
UNH
$353B
$31.2M 2.93%
+100,000
New +$38.2M
VTRS icon
14
Viatris
VTRS
$18.8B
$24.6M 2.31%
2,750,000
-4,750,000
-63% -$40.2M
BKD icon
15
Brookdale Senior Living
BKD
$2.8B
$15M 1.4%
2,150,000
-4,100,000
-66% -$26.7M
ZIMV
16
DELISTED
ZimVie
ZIMV
$15M 1.4%
1,600,000
-285,000
-15% -$2.6M
APLS
17
DELISTED
Apellis Pharmaceuticals
APLS
$14.7M 1.38%
+850,000
New +$15.7M
MYGN icon
18
Myriad Genetics
MYGN
$302M
$10.6M 1%
2,000,000
-350,000
-15% -$2.07M
EVH icon
19
Evolent Health
EVH
$520M
$9.57M 0.9%
850,000
-2,150,000
-72% -$19.7M
CON
20
Concentra Group Holdings
CON
$4.37B
$8.23M 0.77%
400,000
-1,200,000
-75% -$25.6M
INGN icon
21
Inogen
INGN
$146M
$6.85M 0.64%
975,000
– –
DNLI icon
22
Denali Therapeutics
DNLI
$3.84B
$5.6M 0.53%
400,000
-850,000
-68% -$12M
TBPH icon
23
Theravance Biopharma
TBPH
$885M
$4.96M 0.47%
450,000
-550,000
-55% -$5.35M
ANAB icon
24
AnaptysBio
ANAB
$1.67B
$2.77M 0.26%
125,000
-625,000
-83% -$13.1M
OSUR icon
25
OraSure Technologies
OSUR
$248M
$2.7M 0.25%
900,000
– –
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Camber Capital Management held 36 positions worth $1.07B, down 62% from $2.81B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Camber Capital Management withdrew a net $771M in Q2 2025, closing 11 positions and reducing 17 holdings. Its most notable exit was PTC Therapeutics, an estimated $76.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 57% a quarter earlier, followed by Miscellaneous.

Against the trend, Camber Capital Management opened a new position in Icon worth $43.6M.

  • Camber Capital Management's largest Q2 2025 buy was Icon: 300,000 shares worth $43.6M.
  • Camber Capital Management added most to BioMarin Pharmaceuticals in Q2 2025, an estimated $5.89M increase.
  • Camber Capital Management's biggest Q2 2025 reduction was Zimmer Biomet, cutting an estimated $121M.
  • Camber Capital Management fully exited PTC Therapeutics in Q2 2025, selling an estimated $76.4M.
  • Camber Capital Management's ten largest holdings make up 79% of its $1.07B portfolio in Q2 2025.
  • Camber Capital Management opened 4 new positions and closed 11 in Q2 2025.
  • Camber Capital Management's portfolio value fell 62% quarter-over-quarter to $1.07B.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.